coadministered cagrilintide and semaglutide in adults with overweight or obesity Summary of REDEFINE 1 REDEFINE 2 trials CagriSema, presented this week at #ADA2025 and published NEJM: REDEFINE 1: β’ π₯ 3,417 participants with (without diabetes) treated π¨New weight loss drug alert!
Pay in 4 interest-free payments of $6.59 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 5 - Aug 10

























![Retatrutide + Cagrilintide: The Weight Loss Stack Outperforming Ozempic [2026 Protocol]](https://levamedical.com/hs-fs/hubfs/image-png-4.png?width=1218&height=537&name=image-png-4.png)
